Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 1 - 6 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2021.47817 İndeks Tarihi: 16-06-2022

Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic

Öz:
Coronavirus disease-2019 (COVID-19) is a serious cause of respiratory tract infection, and its severe course has been associated with some risk factors, including malignancies and immunosuppressive treatments. Primary cutaneous lymphomas (PCL) are a heterogeneous group of immune system neoplasms, which are subclassified as indolent and aggressive types according to their survival rates. PCL treatment ranges from skin-based therapies to systemic treatments, of which immunosuppressive effects occur in some. During the COVID-19 pandemic, patients with PCL should be protected from possible COVID-19 complications, and the optimal treatment should be provided to control the disease taking into account the treatment-related risks. Therefore, recommendations about the management of patients with PCL during the COVID-19 pandemic were overviewed in light of the literature. Topical treatments can generally be considered low-risk therapies and can be continued without interruption. Phototherapy, skin radiotherapy, and total skin electron beam therapy increase the risk of COVID-19 exposure due to hospital visits. Moderate-risk therapies like interferons, systemic retinoids, methotrexate, and systemic corticosteroids might be used with caution. Advanced-stage patients with COVID-19 related comorbidity and who previously received immunosuppressive therapy should be carefully evaluated. Biological agents and systemic chemotherapeutics, which are considered high-risk, should not be delayed when needed. However, increasing intervals between treatments or switching to alternative therapies may be preferable in stabl
Anahtar Kelime:

-

Öz:
Koronavirüs hastalığı-2019 (COVID-19), solunum yolu enfeksiyonunun ciddi bir nedenidir ve şiddetli seyri, maligniteler ve immünosüpresif tedaviler gibi bazı risk faktörleriyle ilişkilendirilmiştir. Primer kutanöz lenfomalar (PKL), sağkalım oranlarına göre indolent ve agresif tipler olarak sınıflandırılan heterojen bir immün sistem neoplazmaları grubudur. PKL’lerin tedavisi, deriye yönelik tedavilerden sistemik tedavilere kadar uzanır ve bunların bazılarının immünosüpresif etkileri vardır. COVID-19 salgını sırasında, PKL’li hastalar olası COVID-19 komplikasyonlarından korunmalı, tedaviye bağlı riskler de dikkate alınarak hastalığı kontrol altına almak için optimal tedavi sağlanmalıdır. Bu bağlamda, COVID-19 pandemisi sırasında PKL yönetimi ile ilgili önerileri literatür ışığında gözden geçirdik. Topikal tedaviler genellikle düşük riskli tedaviler düşünülebilir ve kesintisiz olarak devam ettirilebilir. Fototerapi, deri radyoterapisi ve total deri elektron ışınlaması tedavileri, hastane ziyareti gerektirdiği için COVID-19’a maruz kalma riskini artırır. İnterferonlar, sistemik retinoidler, metotreksat ve sistemik kortikosteroidler gibi orta riskli tedaviler dikkatle kullanılabilir. COVID-19 ile ilişkili komorbiditeye sahip ileri evre hastalar ve daha önce immünosüpresif tedavi almış hastalar dikkatlice değerlendirilmelidir. Yüksek riskli olduğu düşünülen biyolojik ajanlar ve sistemik kemoterapötikler gerektiğinde geciktirilmemelidir. Bununla birlikte, hastalık stabil ise, tedaviler arasındaki aralıkların uzatılması veya alternatif tedavilere geçiş tercih edilebilir. En önemlisi, PKL’li tüm hastaların pandemi devam ettiği sürece genel koruma önlemlerine uyması
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Huang C, Wang Y, Li X, et al.: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
  • 2. Lu R, Zhao X, Li J, et al.: Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 2020;395:565-74.
  • 3. Jordan RE, Adab P, Cheng KK: COVID-19: Risk factors for severe disease and death. BMJ 2020;368:m1198.
  • 4. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of Coronavirus disease 2019 in China. N Engl J Med 2020;382:1708-20.
  • 5. Willemze R, Cerroni L, Kempf W, et al.: The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019;133:1703-14.
  • 6. Trautinger F, Eder J, Assaf C, et al.: European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. Eur J Cancer 2017;77:57-74.
  • 7. Zic JA, Ai W, Akilov OE, et al.: United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. J Am Acad Dermatol 2020;83:703-4.
  • 8. Papadavid E, Scarisbrick J, Ortiz Romero P, et al.: Management of primary cutaneous lymphoma patients during COVID-19 pandemic: EORTC CLTF guidelines. J Eur Acad Dermatol Venereol 2020;34:1633-6.
  • 9. Seto WH, Tsang D, Yung RW, et al.: Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome (SARS). Lancet 2003;361:1519-20.
  • 10. Mateeva V, Patsatsi A: Management of primary cutaneous lymphomas during the COVID-19 pandemic. Clin Dermatol 2021;39:64-75.
  • 11. Costa FB, Baptista PL, Duquia RP: A cross-sectional questionnaire study in a phototherapy unit during COVID-19. Photochem Photobiol Sci 2021;20:1239-42.
  • 12. Pacifico A, Ardigo M, Frascione P, Damiani G, Morrone A: Phototherapeutic approach to dermatology patients during the 2019 coronavirus pandemic: real-life data from the Italian red zone. Br J Dermatol 2020;183:375-6.
  • 13. Aguilera P, Gilaberte Y, Perez-Ferriols A, et al.: Management of phototherapy units during the COVID-19 pandemic: Recommendations of the AEDV’s Spanish Photobiology Group. Actas Dermosifiliogr (Engl Ed) 2021;112:73-5.
  • 14. Lim HW, Feldman SR, Van Voorhees AS, Gelfand JM: Recommendations for phototherapy during the COVID-19 pandemic. J Am Acad Dermatol 2020;83:287-8.
  • 15. Guideline for disinfection and sterilization in healthcare facilities. [accessed by: 19 November 2011]. https://www.cdc.gov/infectioncontrol/guidelines/ disinfection/tables/table1.html
  • 16. Yang J, Zheng Y, Gou X, et al.: Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020;94:91-5.
  • 17. Wang T, Du Z, Zhu F, et al.: Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 2020;395:e52.
  • 18. Tepasse PR, Hafezi W, Lutz M, et al.: Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 2020;190:185-8.
  • 19. Lancman G, Mascarenhas J, Bar-Natan M: Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia. J Hematol Oncol 2020;13:131.
  • 20. Kos I, Balensiefer B, Roth S, et al.: Prolonged Course of COVID-19-associated pneumonia in a B-cell depleted patient after rituximab. Front Oncol 2020;10:1578.
  • 21. Wilcox RA: Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk- stratification, and management. Am J Hematol 2017;92:1085-102.
  • 22. Patrizi A, Bardazzi F, Filippi F, Abbenante D, Piraccini BM: The COVID-19 outbreak in Italy: Preventive and protective measures adopted by the Dermatology Unit of Bologna University Hospital. Dermatol Ther 2020;33:e13469.
  • 23. Bialynicki-Birula R, Siemasz I, Otlewska A, Matusiak L, Szepietowski JC: Influence of COVID-19 pandemic on hospitalizations at the tertiary dermatology department in south-west Poland. Dermatol Ther 2020;33:e13738.
  • 24. Mateeva V, Vassileva S: Impact of COVID-19 pandemic on the management of cutaneous lymphomas. Clin Dermatol 2021;39:169-71.
  • 25. Hanna TP, King WD, Thibodeau S, et al.: Mortality due to cancer treatment delay: Systematic review and meta-analysis. BMJ 2020;371:m4087.
  • 26. Recommendations of the National Comprehensive Cancer Network® (NCCN®) COVID-19. [accessed by 19 November 2011]. Vaccination Advisory Committee https://www.nccn.org/docs/default-source/covid-19/2021_ covid-19_vaccination_guidance_v2-0.pdf
  • 27. McCaughan G, Di Ciaccio P, Ananda-Rajah M, et al.: COVID-19 vaccination in haematology patients: an Australian and New Zealand consensus position statement. Intern Med J 2021;51:763-8.
  • 28. COVID-19 Vaccines for Moderately to Severely Immunocompromised People. [accessed by 19 November 2011]. https://www.cdc.gov/coronavirus/2019- ncov/vaccines/recommendations/immuno.html
  • 29. Robilotti EV, Babady NE, Mead PA, et al.: Determinants of COVID-19 disease severity in patients with cancer. Nat Med 2020;26:1218
APA ÖRNEK S, BİLGİÇ A, YAZİC S, BAYRAMGÜRLER D, Sanli H, Onsun N (2022). Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. , 1 - 6. 10.4274/turkderm.galenos.2021.47817
Chicago ÖRNEK Sinem,BİLGİÇ Aslı,YAZİC Serkan,BAYRAMGÜRLER Dilek,Sanli Hatice,Onsun Nahide Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. (2022): 1 - 6. 10.4274/turkderm.galenos.2021.47817
MLA ÖRNEK Sinem,BİLGİÇ Aslı,YAZİC Serkan,BAYRAMGÜRLER Dilek,Sanli Hatice,Onsun Nahide Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. , 2022, ss.1 - 6. 10.4274/turkderm.galenos.2021.47817
AMA ÖRNEK S,BİLGİÇ A,YAZİC S,BAYRAMGÜRLER D,Sanli H,Onsun N Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. . 2022; 1 - 6. 10.4274/turkderm.galenos.2021.47817
Vancouver ÖRNEK S,BİLGİÇ A,YAZİC S,BAYRAMGÜRLER D,Sanli H,Onsun N Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. . 2022; 1 - 6. 10.4274/turkderm.galenos.2021.47817
IEEE ÖRNEK S,BİLGİÇ A,YAZİC S,BAYRAMGÜRLER D,Sanli H,Onsun N "Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic." , ss.1 - 6, 2022. 10.4274/turkderm.galenos.2021.47817
ISNAD ÖRNEK, Sinem vd. "Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic". (2022), 1-6. https://doi.org/10.4274/turkderm.galenos.2021.47817
APA ÖRNEK S, BİLGİÇ A, YAZİC S, BAYRAMGÜRLER D, Sanli H, Onsun N (2022). Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 1 - 6. 10.4274/turkderm.galenos.2021.47817
Chicago ÖRNEK Sinem,BİLGİÇ Aslı,YAZİC Serkan,BAYRAMGÜRLER Dilek,Sanli Hatice,Onsun Nahide Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 1 - 6. 10.4274/turkderm.galenos.2021.47817
MLA ÖRNEK Sinem,BİLGİÇ Aslı,YAZİC Serkan,BAYRAMGÜRLER Dilek,Sanli Hatice,Onsun Nahide Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.1 - 6. 10.4274/turkderm.galenos.2021.47817
AMA ÖRNEK S,BİLGİÇ A,YAZİC S,BAYRAMGÜRLER D,Sanli H,Onsun N Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 1 - 6. 10.4274/turkderm.galenos.2021.47817
Vancouver ÖRNEK S,BİLGİÇ A,YAZİC S,BAYRAMGÜRLER D,Sanli H,Onsun N Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 1 - 6. 10.4274/turkderm.galenos.2021.47817
IEEE ÖRNEK S,BİLGİÇ A,YAZİC S,BAYRAMGÜRLER D,Sanli H,Onsun N "Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.1 - 6, 2022. 10.4274/turkderm.galenos.2021.47817
ISNAD ÖRNEK, Sinem vd. "Primary cutaneous lymphomas and Coronavirus disease-2019: A critical overview of primary cutaneous lymphoma management in pandemic". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 1-6. https://doi.org/10.4274/turkderm.galenos.2021.47817